US 12,441,772 B2
Designed ankyrin repeat domain with improved stability
Johannes Schilling, Schlieren (CH); and Marcel Walser, Schlieren (CH)
Assigned to Molecular Partners AG, Schlieren (CH)
Appl. No. 17/596,102
Filed by MOLECULAR PARTNERS AG, Schlieren (CH)
PCT Filed Jun. 3, 2020, PCT No. PCT/EP2020/065314
§ 371(c)(1), (2) Date Dec. 2, 2021,
PCT Pub. No. WO2020/245171, PCT Pub. Date Dec. 10, 2020.
Claims priority of application No. 19178282 (EP), filed on Jun. 4, 2019.
Prior Publication US 2024/0124535 A1, Apr. 18, 2024
Int. Cl. C07K 14/00 (2006.01); C07K 14/47 (2006.01); A61K 38/00 (2006.01); C07K 14/435 (2006.01); C07K 14/765 (2006.01)
CPC C07K 14/47 (2013.01) [A61K 38/00 (2013.01); C07K 14/435 (2013.01); C07K 14/765 (2013.01); C07K 2319/35 (2013.01); C07K 2319/70 (2013.01)] 17 Claims
 
1. A designed ankyrin repeat domain with binding specificity for serum albumin, wherein said designed ankyrin repeat domain comprises an amino acid sequence that has at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 3 or 4, and wherein said designed ankyrin repeat domain (i) has an aspartic acid (D) at the position corresponding to position 77 of SEQ ID NO: 3 and has an alanine (A) at the position corresponding to position 78 of SEQ ID NO: 3; or (ii) has an alanine (A) at the position corresponding to position 77 of SEQ ID NO: 4 and has an aspartic acid (D) at the position corresponding to position 78 of SEQ ID NO: 4.